<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03716791</url>
  </required_header>
  <id_info>
    <org_study_id>16970-001</org_study_id>
    <nct_id>NCT03716791</nct_id>
  </id_info>
  <brief_title>The Effect of Methylsulfonylmethane (MSM) on Cardiometabolic Health</brief_title>
  <official_title>The Effect of Methylsulfonylmethane (MSM) on Cardiometabolic Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lindsey Miller</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity- related diseases are linked to elevated levels of inflammation, oxidative stress,&#xD;
      and metabolic dysfunction. Methylsulfonylmethane (MSM) is a naturally occurring compound that&#xD;
      demonstrates antioxidant and anti-inflammatory effects. Improvements in measures of metabolic&#xD;
      health have been observed in mouse models of obesity and type 2 diabetes following MSM&#xD;
      treatment. However, the effect of MSM on obesity-related risk factors for disease in humans&#xD;
      has not been investigated. Therefore, the purpose of this investigation will be to determine&#xD;
      whether MSM supplementation improves metabolic health, and markers of inflammation and&#xD;
      oxidative status.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 19, 2019</start_date>
  <completion_date type="Actual">August 11, 2021</completion_date>
  <primary_completion_date type="Actual">January 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind placebo controlled randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline blood glucose at 4, 8, and 16 weeks</measure>
    <time_frame>0,4,8,16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline blood cholesterol at 4, 8, and 16 weeks</measure>
    <time_frame>0,4,8,16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline blood pressure at 4, 8, and 16 weeks</measure>
    <time_frame>0,4,8,16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline insulin at 4, 8, and 16 weeks</measure>
    <time_frame>0,4,8,16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline resting metabolic rate at 16 weeks</measure>
    <time_frame>0 and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline percent body fat at 4, 8, and 16 weeks</measure>
    <time_frame>0,4,8,16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in waist circumference at 4, 8, and 16 weeks</measure>
    <time_frame>0,4,8,16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood markers of inflammation and oxidative stress at 4, 8, and 16 weeks</measure>
    <time_frame>0,4,8,16 weeks</time_frame>
    <description>Inflammatory markers will include c-reactive protein, interleukin-6, and Tumor necrosis factor-alpha. Oxidative stress will be determined by total antioxidant capacity assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pulmonary function tests</measure>
    <time_frame>0, 4, 8, 16 weeks</time_frame>
    <description>Pulmonary function tests include forced expiratory volume in 1 second to forced vital capacity ration and slow vital capacity measurement. Expired nitric oxide has also been included as a marker of pulmonary inflammation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>pill capsules containing white rice flour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylsulfonylmethane Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pill capsules containing MSM</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>methylsulfonylmethane</intervention_name>
    <description>3g per day</description>
    <arm_group_label>Methylsulfonylmethane Group</arm_group_label>
    <other_name>MSM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>white rice flour</description>
    <arm_group_label>Placebo Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  overweight or obese adults without any diagnosed disease or current medications other&#xD;
             than birth control. Participants must agree to maintain diet and physical activity&#xD;
             levels throughout study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  normal weight adults, or overweight/obese adults that do not meet the criteria for&#xD;
             metabolically unhealthy obesity. Individuals currently on medications, or with&#xD;
             diagnosed disease. Pregnant or nursing women, or women planning to become pregnant&#xD;
             within the study timeframe. Lack of access to reliable transportation to study site,&#xD;
             lack of internet access, or non-english speaking.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsey E Miller, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington State University</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 18, 2018</study_first_submitted>
  <study_first_submitted_qc>October 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2018</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Washington State University</investigator_affiliation>
    <investigator_full_name>Lindsey Miller</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dimethyl sulfone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

